Chaoqun Huang1,2,3, Yao Min4, Jiuyang Liu2,3,5, Jing Li6, Xiaojun Yang1,2,7. 1. Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, PR China. 2. Key Laboratory of Tumor Biological Behavior of Hubei Provence, Wuhan, Hubei Province, PR China. 3. Clinical Cancer Study Center of Hubei Provence, Wuhan, Hubei Province, PR China. 4. The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, PR China. 5. Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, PR China. 6. The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, PR China. lijing1982wh@163.com. 7. Clinical Cancer Study Center of Hubei Provence, Wuhan, Hubei Province, PR China. yangxj688@163.com.
Abstract
BACKGROUND: Colorectal cancer (CRC) is the most common cancer of the digestive system. However, effective therapeutic targets against CRC have not been found yet. Further, the relationship between the expression of ring finger protein 126 (RNF126) and CRC is not clear. MATERIAL AND METHODS: The expression level of RNF126 in CRC tissues and cell lines was detected by immunohistochemical staining and western blot. Subsequently, endogenous RNF126 expression was inhibited in a CRC cell line using a short hairpin RNA. Next, the effect of RNF126 on the properties of CRC cells was studied through different experimental methods. RESULTS: We found that the RNF126 protein was mainly localized in the cytoplasm. High RNF126 expression was observed to be an independent risk factor for poor prognosis in CRC patients. In vitro studies showed that RNF126 was able to promote the proliferation, migration, and invasion ability of CRC cells. CONCLUSION: RNF126 acts as an oncogene during CRC development, and may serve as a novel target for CRC treatment.
BACKGROUND: Colorectal cancer (CRC) is the most common cancer of the digestive system. However, effective therapeutic targets against CRC have not been found yet. Further, the relationship between the expression of ring finger protein 126 (RNF126) and CRC is not clear. MATERIAL AND METHODS: The expression level of RNF126 in CRC tissues and cell lines was detected by immunohistochemical staining and western blot. Subsequently, endogenous RNF126 expression was inhibited in a CRC cell line using a short hairpin RNA. Next, the effect of RNF126 on the properties of CRC cells was studied through different experimental methods. RESULTS: We found that the RNF126 protein was mainly localized in the cytoplasm. High RNF126 expression was observed to be an independent risk factor for poor prognosis in CRC patients. In vitro studies showed that RNF126 was able to promote the proliferation, migration, and invasion ability of CRC cells. CONCLUSION: RNF126 acts as an oncogene during CRC development, and may serve as a novel target for CRC treatment.
Authors: Rebecca K Delker; Yanjiao Zhou; Alexandros Strikoudis; C Erec Stebbins; F Nina Papavasiliou Journal: Proc Natl Acad Sci U S A Date: 2012-12-31 Impact factor: 11.205
Authors: Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2016-06-02 Impact factor: 508.702